文献速递乳腺癌

曲妥珠单抗美坦新辅助或不联合帕妥珠单抗对比曲妥珠单抗联合紫杉类治疗人表皮生长因子受体2阳性晚期乳腺癌:III期MARIANNE研究主要结果

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
PubMed 文献 · J Clin Oncol · 2016-11-07

MARIANNE研究纳入1095例既往未接受过晚期治疗、中心评估HER2阳性的晚期乳腺癌患者,随机1:1:1接受曲妥珠单抗联合紫杉类(对照组)、T-DM1联合安慰剂或T-DM1联合帕妥珠单抗。T-DM1±帕妥珠单抗的无进展生存期非劣效于对照组但未显示优效,且耐受性更好。

要点

  • T-DM1和T-DM1联合帕妥珠单抗的中位无进展生存期分别为14.1个月和15.2个月,对照组为13.7个月,均非劣效但未优效。
  • 对照组客观缓解率为67.9%,T-DM1组为59.7%,T-DM1联合帕妥珠单抗组为64.2%。
  • T-DM1组3级及以上不良事件发生率数值上低于对照组(45.4%和46.2%对54.1%),生活质量维持更久。

核心结论

  • T-DM1在HER2阳性晚期乳腺癌一线治疗中疗效非劣效于紫杉类联合曲妥珠单抗但未显示优效,且耐受性更好。

研究设计与样本

  • MARIANNE是一项III期随机对照研究,纳入1095例中心评估HER2阳性、既往未接受过晚期治疗的晚期乳腺癌患者,按1:1:1随机分配至对照组(曲妥珠单抗联合紫杉类)、T-DM1联合安慰剂组(以下称T-DM1组)或T-DM1联合帕妥珠单抗组,均使用标准剂量。
  • 主要终点为独立评审评估的无进展生存期。

主要发现

  • 中位无进展生存期:对照组13.7个月,T-DM1组14.1个月,T-DM1联合帕妥珠单抗组15.2个月;两个试验组相比对照组均为非劣效,但均未显示优效。
  • 客观缓解率:对照组67.9%,T-DM1组59.7%,T-DM1联合帕妥珠单抗组64.2%;中位缓解持续时间分别为12.5个月、20.7个月和21.2个月。
  • 3级及以上不良事件发生率:对照组54.1%,T-DM1组45.4%,T-DM1联合帕妥珠单抗组46.2%,对照组数值上更高。
  • 因不良事件终止治疗的患者在T-DM1组数值上更少,且T-DM1组健康相关生活质量维持时间更长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the properties of trastuzumab with the cytotoxic activity of DM1. T-DM1 demonstrated encouraging efficacy and safety in a phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Combination T-DM1 and pertuzumab showed synergistic activity in cell culture models and had an acceptable safety profile in a phase Ib and II study. Methods In the MARIANNE study, 1,095 patients with centrally assessed, HER2-positive, advanced breast cancer and no prior therapy for advanced disease were randomly assigned 1:1:1 to control (trastuzumab plus taxane), T-DM1 plus placebo, hereafter T-DM1, or T-DM1 plus pertuzumab at standard doses. Primary end point was progression-free survival (PFS), as assessed by independent review. Results T-DM1 and T-DM1 plus pertuzumab showed noninferior PFS compared with trastuzumab plus taxane (median PFS: 13.7 months with trastuzumab plus taxane, 14.1 months with T-DM1, and 15.2 months with T-DM1 plus pertuzumab). Neither experimental arm showed PFS superiority to trastuzumab plus taxane. Response rate was 67.9% in patients who were treated with trastuzumab plus taxane, 59.7% with T-DM1, and 64.2% with T-DM1 plus pertuzumab; median response duration was 12.5 months, 20.7 months, and 21.2 months, respectively. The incidence of grade ≥ 3 adverse events was numerically higher in the control arm (54.1%) versus the T-DM1 arm (45.4%) and T-DM1 plus pertuzumab arm (46.2%). Numerically fewer patients discontinued treatment because of adverse events in the T-DM1 arms, and health-related quality of life was maintained for longer in the T-DM1 arms. Conclusion T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol. 2016. PMID: 28056202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。